Home | Careers | BI | Contact us

Sativex® receives regulatory approval in Israel

June 13, 2012

Neopharm Group and GW Pharmaceuticals plc announced that Sativex┬« (Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) oromucosal spray) has received regulatory approval from the Israeli Ministry of Health for the treatment of spasticity and neuropathic pain due…

Home | About Us | Companies | Partnering | Research | Corporate Citizenship | Careers | Newsroom | Contact | Legal Notice

All Rights reserved, Neopharm Group, Israel | Design by: VAZA | Developed by: The Shark Lady